T细胞钾离子通道的生理学及药理学研究进展

中国临床药理学与治疗学 ›› 2012, Vol. 17 ›› Issue (3): 352-356.

T细胞钾离子通道的生理学及药理学研究进展

邱红霞, 赵阴环, 朱桂启, 赵海慧

哈尔滨医科大学附属二院风湿免疫科,哈尔滨 150086,黑龙江

收稿日期:2011-10-06 修回日期:2011-11-21 出版日期:2012-03-26 发布日期:2012-04-20
通讯作者: 赵阴环,男,博士,主任医师,研究方向:系统性红斑狼疮发病机制及治疗。Tel: 15114570787, E-mail: zhaoyinhuan@medmail.com
作者简介:邱红霞,女,硕士研究生,研究方向:外固血T细胞钾离子通道的生理学及药理学作用。Tel: 15244602325, E-mail: xia1015q@yahoo.com.cn
基金资助:
黑龙江省自然科学基金重点项目(ZD200814-01)

The physiology and pharmacology research puogression of T-ceu potassium channel

QIU Hong-xia, ZHAO Yin-huan, ZHU Gui-qi, ZHAO Hai-hui

Department of Rheumatology, the 2nd Affiliated Hospital of Harbin Medicou University, Harbin 150086, Heilongjiang, China

Received:2011-10-06 Revised:2011-11-21 Online:2012-03-26 Published:2012-04-20

摘要/Abstract

摘要： 在T淋巴细胞不同的活化和分化状态,电压依赖性Kv1.3通道和Ca²⁺活化IKCa1 通道的表达存在差异。细胞从初始状态分化为记忆状态以及从静止转化为激活的过程中,钾通道的表达发生转变。Kv1.3和IKCa1与T细胞活化密切相关,选择性钾通道阻断剂可用于自身免疫性疾病等多种疾病的治疗。本文回顾了钾离子通道在初始T细胞和记忆性T细胞中的功能,描述选择性Kv1.3和IKCa1通道阻断剂的进展以及这些阻断剂潜在的免疫治疗的理论基础。

关键词: T淋巴细胞, 钾离子通道, 钾离子通道阻断剂

Abstract: The voltage-gated Kv1.3 channel and the Ca²⁺-activated IKCa1 K⁺ channel are expressed in T cells in a distinct pattern that depends on the state of lymphocyte activation and differentiation. The channel phenotype changes during the progression from the resting to the activated cell state and from naïve to effector memory cells. Kv1.3 and IKCa1 channel are related to the activation of T lymphocyte, and the specific K⁺ channel blockers can be used in the therapy of many diseases such as autoimmune diseases. In this article, we review the functional roles of these channels in both naïve cells and memory cells, describe the development of selective inhibitors of Kv1.3 and IKCa1 channels, and provide a rationale for the potential therapeutic use of these inhibitors in immunological disorders.

Key words: T lymphocyte, K⁺ channel, Inhibitors of K⁺ channel

中图分类号:

R331

邱红霞, 赵阴环, 朱桂启, 赵海慧. T细胞钾离子通道的生理学及药理学研究进展[J]. 中国临床药理学与治疗学, 2012, 17(3): 352-356.

QIU Hong-xia, ZHAO Yin-huan, ZHU Gui-qi, ZHAO Hai-hui. The physiology and pharmacology research puogression of T-ceu potassium channel[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(3): 352-356.

参考文献

[1] Mello de Queiroz F, Ponte CG, Bonomo A, et al. Study of membrane potential in T lymphocytes subpopulations using flow cytometry[J].BMC Immunology,2008,9(63):1471-2172.
[2] Nicolaou SA, Neumeier L, Steckly A, et al. Localization of Kv1.3 channels in the immunological synapse modulates the calcium response to antigen stimulation in T lymphocytes [J]. Immunol, 2009, 183(10):6296-6302.
[3] Chandy KG, Wulff H, Beeton C, et al. K⁺ channels as targets for specific immunomodulation [J].Trends Pharmacol Sci, 2004, 25(5):280-289.
[4] 郑付春,贾强用,石刚刚.Ca²⁺/PKC通路在大鼠缺氧复氧心肌细胞Egr-1高表达中的作用[J]. 中国临床药理学与治疗学, 2011,V16(3): 241-248.
[5] Nicolaou SA, Neumeier L, Takimoto K, et al. Differential calcium signaling and Kv1.3 trafficking to the immunological synapse in systemic lupus erythematosus[J].Cell Calcium,2010,47(1):19-28.
[6] Panyi G, Possani LD, Rodríguez de la Vega RC, et al. K⁺ channel blockers: Novel tools to inhibit T cell activation leading to specific immunosuppression[J]. Curr Pharm Des, 2006,12(18):2199-2220.
[7] Dauplais M,Lecoq A,Song J,et al. On the convergent evolution of animal toxins.Conservation of a diad of functional residues in potassium channel-blocking toxins with unrelated structures[J]. Biochemistry, 1997, 72(7):4302-4309.
[8] Beeton C, Smith BJ, Sabo JK, et al. The D-Diastereomer of ShK Toxin Selectively Bolcks Voltage-gated K⁺ Channels and Inhibits T Lymphocyte Proliferation[J]. J Biol Chem, 2008,283(2):988-997.
[9] Pennington MW, Beeton C, Galea CA, et al. Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes[J]. Mol Pharmacol, 2009, 75(4):762-773.
[10] Han S, Yi H, Yin SJ, et al. Structural basis of a potent peptide inhibitor designed for Kv1.3 channel, a therapeutic target of autoimmune disease [J]. J Biol Chem, 2008, 283(27):19058-19065.
[11] Mix E,Goertsches R,Zettl UK. Immunology and neurology[J]. Neurology, 2007, 254(Suppl 2):112-117.
[12] Schmitz A, Sankaranarayanan A, Azam P, et al. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases[J].Mol Pharmacol,2005,68(5):1254-1270.
[13] Azam P, Sankaranarayanan A, Homerick D, et al. Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis[J]. J Invest Dermatol, 2007,127(6):1419-1429.
[14] Ahn HS, Kim SE, Choi BH, et al. Calcineurin- independent inhibition of Kv1.3 by FK-506(tacrolimus):a novel pharmacological property[J].Am J Physiol Cell Physiol, 2007, 292(5):C 1714-C1722.
[15] Wulff H, Beeton C, Chandy KG. Potassium channels as therapeutic targets for autoimmune disorders [J]. Curr Opin Drug Discov Dev, 2003,6(5): 640-647.
[16] Wulff H, Miller MJ, Hansel W, et al. Design of a potent and selective inhibitor of the intermediate-conductance Ca²⁺ -activated K⁺ channel, IKCa1: A potential immunosuppressant[J].Proc Natl Acad Sci USA, 2000, 97(14):8151-8156.
[17] Wulff H, Gutman GA, Cahalan MD, et al. Delineation of the clotrimazole/TRAM-34 binding site on the intermediate conductance calcium-activated potassium channel IKCa1 [J]. Biol Chem, 2001,276(34): 32040-32045.
[18] Kohler R, Wulff H, Eichler I, et al. Blockade of the intermediate- conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis[J].Circulation, 2003,108(9):1119-1125.
[19] Urbahns K, Horvath E, Stasch JP, et al. 4-Phenyl-4H-pyrans as IKCa channel blockers. [J].Bioorg Med Chem Lett, 2003,13(16):2637-2639.
[20] Grgic I,Wulff H,Eichler I, et al. Blockade of T-Lymphocyte KCa3.1 and Kv1.3 channels as novel immunosuppression strategy to prevent kidney allograft rejection[J]. Transplant Proc,2009,41(6):2601-2606.
[21] Beeton C, Wulff H, Barbaria J, et al. Selective blockade of T lymphocyte K⁺ channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis[J]. Proc Natl Acad Sci USA, 2001,98(24): 13942-13947.
[22] Rus H, Pardo CA, Hu L, et al. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain[J].Proc Natl Acad Sci,2005,102(31):11094-11099.
[23] 胡晓静.T细胞电压门控钾通道Kv1.3在再生障碍性贫血中的作用研究[D].内科学(血液病),2009
[24] Beeton C, Pennington MW, Wulff H, et al. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases[J]. Mol Pharmacol, 2005, 67(4): 1369-1381.
[25] Schmitz A, Sankaranarayanan A, Azam P, et al. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases[J]. Mol Pharmacol, 2005, 68(5): 1254-1270.
[26] Beeton C, Wulff H, Standifer NE, et al. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases[J]. PNAS, 2006, 103(46): 17414-17419.
[27] Gilhar A, Bergman R, Assay B, et al. The beneficial effect of blocking Kv1.3 in the psoriasiform SCID mouse model[J]. J Invest Dermatol, 2011,131(1):118-124.
[28] Matheu MP, Beeton C, Garcia A, et al. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block[J].Immunity,2008, 29(4) 602-614.